共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
在目前的医学水平对于许多癌症尚无有效的根治方法之时,癌症,无论对于癌症患者还是家属来说,无疑都是一个“鬼门关”。但现在这个“鬼门关”与以往的“鬼门关”意义有很大差别。现代医学研究证明,癌症中的l/3是可以预防的;癌症患者中1/3如果早期发现是可以治愈的;另外1/3可以通过姑息治疗减轻症状,获得较好的生活质量。那作为癌症患者的家属,如何帮助患者一起渡过这个“鬼门关”,取得较好的治疗效果呢? 相似文献
4.
5.
6.
7.
8.
目的:探讨中晚期癌症患者首次住院期间心理健康状况及其影响因素。方法:对120名中晚期首次住院进行放化疗的癌症患者,在治疗前、中、后三个时期采用SCL-90量表进行自评式心理健康状况调查研究。结果:SCL-90量表调查显示中晚期癌症患者治疗前心理健康状况明显差于治疗后状况,与SCL-90常模比较表现为异常的心理状态。单因素方差分析得出血红蛋白水平、疼痛状况、家庭及社会支持、自我评价状况、营养状态、行为状态、年龄、医疗报销、性别及知情状况等十一个因素对患者心理健康影响较大,多元逐步回归分析提示在不同治疗时期影响心理健康状况的主要因素又不尽相同。结论:在癌症治疗过程中缺乏家庭及社会支持、疼痛、贫血、营养状态差及较差的经济状况等因素对中晚期癌症患者心理健康可造成较大的负面影响。 相似文献
9.
10.
11.
我第一次出版《应对癌症对情绪的影响:做一个积极的病人,对自己的治疗负责》这本书是在1984年。那时,癌症一词与耻辱相关的感觉非常强烈,以至于我不得不为了将癌症这个词写在标题上而竭力相争。25年前, 相似文献
12.
Shejuan An Jianquan Zhu Zhihong Chen Guochun Zhang Zhen Wang Yilong Wu 《中德临床肿瘤学杂志》2008,7(12):677-681
Objective: To investigate whether laminin 5 (LN5) might be a predictor in lung cancer patient treated with gefitinib and estimate the underlying mechanisms. Methods: LN5 and epidermal growth factor receptor (EGFR) mRNA expression level were detected in the tumor tissues of lung cancer patients who underwent surgery resection prior to gefitinib treatment. EGFR exon 19 and 21 mutation status was also detected in these specimens. The association between LN5, EGFR mRNA expression level, EGFR mutation and gefitinib treatment response were evaluated. In vitro study were carried by adding exog- enous LN5 and gefitinib to A549 lung cancer cell line, and Western-blotting was performed to investigate the phosphorylation level of EGFR,Ak, and Erk. Results: The disease control rate according to LN5 mRNA level was 52.9% for the below cut- point group, and 17.6% for the above cut-point (P = 0.009). The in vitro study showed that exogenous LN5 can neutralize the inhibition of phosphor-Akt by gefitinib. Conclusion: Patients with lower LN5 mRNA level would likely benefit from gefitinib. In vitro study indicated that the inhibition of Akt induced by gefitinib might be reversed by LN5. These results provide important insights into the molecular mechanisms underlying sensitivity to gefitinib in lung cancer patients. 相似文献
13.
14.
我科于1982年12月~1992年12月收治首程单纯放疗食管癌患者480例,其中生存5年以上者49例,现报告如下:1 材料和方法1.1 临床资料 本组49例中,男性38例,女性13例;治疗时年龄为23岁~83岁,49岁以下者13例,50岁~59岁17例,60岁~69岁15例,70岁以上者4例,中位年龄53岁.病变长度短于5cm者28例,5~8cm者18例,>8cm者3例(1例长达11cm).放疗前发现锁骨上转移者4例,左下颈转移1例.1例食管中段癌放疗后13年局部复发再行放疗后生存5年以上. 相似文献
15.
16.
19.
20.
Xiaomei Li Duanqi Liu 《中德临床肿瘤学杂志》2007,6(3):P293-P295
Objective: To evaluate the analgesic efficacy as well as adverse effects of OxyContin for the treatment of moderate to severe cancer pain. Methods: OxyContin was administered at an initial dose of 10 mg every 12 h and titrated upwards according to the extent of pain relief. The analgesic effect, Karnofsky performance status (KPS) scale as well as adverse effects were investigated. Results: The mean onset time and duration of analgesic effect was 41 min and 12.6 h, respectively, with the daily average dose of 69.03 mg. Among all the 31 patients who had suffered moderate to severe pain, slight pain relief was achieved in one patient (3.23 %). Moderate, obvious and complete pain relief were achieved in 4 (12.90 %), 20 (64.52 %) and 6 (19.53%), respectively. KPS was elevated in 19 (61.29%) and stable in 9 (29.03%) patients after administration of OxyContin. 3 (9.68%) patients were died of disease deterioration. Main adverse effect was constipation in 10 cases (32.26%). Conclusion: OxyContin was effective in the treatment of moderate to severe cancer pain, with rapid onset, good analgesic performance, mild adverse effect and safety profile. 相似文献